Latest Information Update: 27 Jul 1999
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Contrast media
- Mechanism of Action Ultrasonography enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 27 Jul 1999 No Development Reported - Investigation in Cancer (diagnosis) in USA (unspecified route)
- 09 Apr 1997 Investigation in Cancer (diagnosis) in USA (unspecified route)